LakeShore Biopharma Files 6-K Amidst Preliminary Proposal
Ticker: LSBWF · Form: 6-K · Filed: Aug 18, 2025 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, corporate-action, press-release
TL;DR
LakeShore Biopharma received a preliminary non-binding proposal, filing a 6-K on 8/18/25.
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on August 18, 2025. The filing includes a press release announcing the receipt of a preliminary non-binding proposal. The company is incorporated in E9 and its fiscal year ends on March 31.
Why It Matters
This filing indicates potential strategic activity or a significant development for LakeShore Biopharma, which could impact its future direction and shareholder value.
Risk Assessment
Risk Level: medium — The filing itself is routine, but the mention of a 'preliminary non-binding proposal' suggests potential corporate actions that carry inherent uncertainty and risk.
Key Numbers
- 001-41598 — SEC File Number (Identifies the specific SEC filing for LakeShore Biopharma)
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Filer of the 6-K
- YS Biopharma Co., Ltd. (company) — Former company name
- YishengBio Co., Ltd (company) — Former company name
- August 18, 2025 (date) — Filing date
- 001-41598 (other) — SEC file number
FAQ
What is the nature of the preliminary non-binding proposal received by LakeShore Biopharma?
The filing does not disclose the specific nature or terms of the preliminary non-binding proposal, only that one was received.
When was LakeShore Biopharma Co., Ltd. formerly known as YS Biopharma Co., Ltd. and YishengBio Co., Ltd.?
The company changed its name from YishengBio Co., Ltd. on March 10, 2023, and from YS Biopharma Co., Ltd. on September 12, 2022.
What is the principal executive office address for LakeShore Biopharma?
The principal executive offices are located at Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
What is the SIC code for LakeShore Biopharma?
The Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Does LakeShore Biopharma file annual reports under Form 20-F or 40-F?
LakeShore Biopharma indicates it files annual reports under cover of Form 20-F.
Filing Stats: 177 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2025-08-18 08:36:53
Filing Documents
- ea0253678-6k_lakeshore.htm (6-K) — 10KB
- ea025367801ex99-1_lakeshore.htm (EX-99.1) — 21KB
- 0001213900-25-077723.txt ( ) — 32KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission file number: 001-41598 LAKESHORE BIOPHARMA CO., LTD (Exact name of registrant as specified in its charter) Building No. 2, 38 Yongda Road Daxing Biomedical Industry Park Daxing District, Beijing, PRC Tel: 010-89202086 (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F EXHIBITS Exhibit No. Description 99.1 Press Release - LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company 1 Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. LakeShore Biopharma Co., Ltd By: /s/ Rachel Yu Name: Rachel Yu Title: Director and Chief Financial Officer Date: August 18, 2025 2